Hydroxychloroquine and Azithromycin as a Treatment of COVID-19

1 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial a,b$ a,c$ a,b a,b,d Philippe Gautret , Jean-Christophe Lagier , Philippe Parola , Van Thuan Hoang , Line a a a e,f,g h Meddeb , Morgane Mailhe , Barbara Doudier , Johan Courjon , Valérie Giordanengo , Vera a a,c i,j a,c Esteves Vieira , Hervé Tissot Dupont , Stéphane Honoré , Philippe Colson , Eric a,c a,c a,c a,c a,c* Chabrière , Bernard La Scola , Jean-Marc Rolain , Philippe Brouqui , Didier Raoult . aIHU-Méditerranée Infection, Marseille, France. bAix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France. cAix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. dThai Binh University of Medicine and Pharmacy, Thai Binh, Viet Nam eInfectiologie, Hôpital de l’Archet, Centre Hospitalier Universitaire de Nice, Nice, France f Université Côte d’Azur, Nice, France g U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Virulence Microbienne et Signalisation Inflammatoire, INSERM, Nice, France hDepartment of Virology, Biological and Pathological Center, Centre Hospitalier Universitaire de Nice, 06200 Nice, France. iService Pharmacie, Hôpital Timone, AP-HM, Marseille, France jLaboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France. $equal work *Corresponding author: